Figure 5.

Blockade of C5aR1 signaling at E12.5–E14.5 causes behavioral changes in adult mice. A, Schema of the experimental process. Briefly, 1 mg · kg⁻¹ · d⁻¹ of the C5aR1 antagonist PMX53 was delivered by intraperitoneal injection to pregnant dams at E12.5–E14.5. Resultant litters were taken through behavioral testing from 6 to 8 weeks and killed, and brains were prepared for ex vivo MRI. Data show results for vehicle (V, black bars)- and PMX53 (P, gray bars)-treated mice. B, Sox2/DCX ratio of the ventricular zone of E16.5 embryos. C, D, F, No change in postnatal growth (C), litter size (D), and snout-occiput length (F) was seen. E, A significant reduction in crown-rump length was observed. G, No difference between treatment groups was found in grip strength for both forelimb (F) and hindlimb (H). H, Time to cross balance beam was increased in male animals from PMX53-treated litters. I, Footfall errors crossing balance beam. J–L, Distance moved in center of open-field arena (J), frequency of entry to novel arm Y-maze (K), and time spent immobile during the forced swim test (L) were significantly different in PMX53-treated litters. Veh., Vehicle; Fem., female. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.